Does discordancy between the CD4 count and CD4 percentage in HIV-positive individuals influence outcomes on highly active antiretroviral therapy?

Journal of Infectious Diseases

Volumn 205, Issue 4, 2012, Pages 540-547

  Gompels, Mark ^a   Dunn, David T ^b   Phillips, Andrew ^c   Dooley, Debbie ^a   De Burgh Thomas, Andrew ^d   Anderson, Jane ^e   Post, Frank ^f   Pillay, Deenan ^g   Gazzard, Brian ^h   Hill, Teresa ^c   Johnson, Margaret ⁱ   Gilson, Richard ^g   Bansi, Loveleen ^c   Easterbrook, Philippa ^f   Fisher, Martin ^j   Walsh, John ^k   Orkin, Chloe ^l   Ainsworth, Jonathan ^m   Leen, Clifford ⁿ   Sabin, Caroline ^c  

^a NORTH BRISTOL NHS TRUST   (United Kingdom)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d Gloucester NHS Trust   (United Kingdom)

^e HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^f KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

ⁱ ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^j UK   (United States)

^k IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^l BARTS HEALTH NHS TRUST   (United Kingdom)

^m NORTH MIDDLESEX UNIVERSITY HOSPITAL NHS TRUST   (United Kingdom)

ⁿ NHS LOTHIAN   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGE DISTRIBUTION; ARTICLE; CAUCASIAN; CD4 LYMPHOCYTE COUNT; CD4 LYMPHOCYTE PERCENTAGE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; ETHNIC DIFFERENCE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; NEGRO; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; REBOUND; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG MONITORING; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84863052744     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir380     Document Type: Article

References (27)

1. Gebo KA, Gallant JE, Keruly JC, Moore RD. Absolute CD4 vs. CD4 percentage for predicting the risk of opportunistic illness in HIV infection. J Acquir Immune Defic Syndr 2004; 36:1028-33. (Pubitemid 38989368)
2. Hulgan T, Shepherd BE, Raffanti SP, et al. Absolute count and percentage of CD41 lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy. J Infect Dis 2007; 195:425-31. (Pubitemid 46146121)
3. Hulgan T, Raffanti S, Kheshti A, et al. CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts .350 lymphocytes/mm3. J Infect Dis 2005; 192:950-7. (Pubitemid 41266790)
4. Taylor JM, Fahey JL, Detels R, Giorgi JV. CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use. J Acquir Immune Defic Syndr 1989; 2:114-24. (Pubitemid 19127086)
5. Burcham J, Marmor M, Dubin N, et al. CD4% is the best predictor of development of AIDS in a cohort of HIV-infected homosexual men. AIDS 1991; 5:365-72.
6. Moore D, Hogg R, Yip B, Craib K, Wood E, Montaner J. CD4 percentage is an independent predictor of survival in patients starting antiretroviral therapy with absolute CD4 cell counts between 200 and 350 cells/ml. HIV Med 2006; 7:383-8. (Pubitemid 44123249)
7. Goicoechea M, Haubrich R. CD4 lymphocyte percentage versus absolute CD4 lymphocyte count in predicting HIV disease progression: an old debate revisited. J Infect Dis 2005; 192:945-7. (Pubitemid 41266788)
8. Hammer SM, Eron JJ, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA Panel. JAMA 2008; 300:555-70.
9. Le TP, Tribble DR, Zhou SYJ, et al. Clinical significance of discordant CD4 count and CD4 percentage in HIV-infected individuals. AIDS 1997; 11:1395-6. (Pubitemid 27423302)
10. The UK Collaborative HIV Cohort Steering Committee. The creation of a large UK-based multicentre cohort of HIV-infected individuals: The UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med 2004; 5:115-24.
11. Chene G, Sterne JA, May M, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 2003; 362:679-86.
12. Guiguet M, Kendjo E, Carcelain G, et al. CD41 T-cell percentage is an independent predictor of clinical progression in AIDS-free antiretroviral-naive patients with CD41 T-cell counts .200 cells/mm3. Antivir Ther 2009; 14:451-7.
13. Bofill M, Janossy G, Lee CA, et al. Laboratory control values for CD4 and CD8 T lymphocytes. Implications for HIV-1 diagnosis. Clin Exp Immunol 1992; 88:243-52.
14. Mili F, FlandersWD, Boring JR, Annest JL, Destefano F. The associations of age, cigarette smoking, and smoking cessation to measures of the immune system in middle-aged men. Clin Immunol Immunopathol 1991; 59:187-200.
15. Vedel SJ, Tholstrup D, Kolte L, et al. Limited impact of the thymus on immunological recovery during and after chemotherapy in patients with diffuse large B-cell lymphoma. Scand J Immunol 2009; 69:547-54.
16. Chevret S, Roquin H, Ganne P, Lefrere JJ. Prognostic value of an elevated CD8 lymphocyte count in HIV infection. Results of a prospective study of 152 asymptomatic HIV-positive individuals. AIDS 1992; 6:1349-52.
17. Margolick JB, Gange SJ, Detels R, O'Gorman MR, RInaldo CR Jr, Lai S. Impact of inversion of the CD4/CD8 ratio on the natural history of HIV-1 infection. J Acquir Immune Defic Syndr 2006; 42:620-6. (Pubitemid 44162434)
18. Stebbing J, Sawleshwarkar S, Michailidis C, et al. Assessment of the efficacy of total lymphocyte counts as predictors of AIDS defining infections in HIV-1 infected people. Postgrad Med 2005; 81:586-8. (Pubitemid 41297915)
19. Maini MK, Gilson RJ, Chavda N, et al. Reference ranges and sources of variability of CD4 counts in HIV-seronegative women and men. Genitourin Med 1996; 72:27-31. (Pubitemid 26057871)
20. Jentsch-Ullrich K, Koenigsmann M, Mohren M, Franke A. Lymphocyte subsets' reference ranges in an age-and gender-balanced population of 100 healthy adults-A monocentric German study. Clin Immunol 2005; 116:192-7. (Pubitemid 40910245)
21. Reichert T, DeBruyère M, Deneys V, et al. Lymphocyte subsets' reference ranges in an age-and gender-balanced population of 100 healthy adults-a monocentric German study. Clin Immunol Immunopathol 1991; 60:190-208.
22. Prins M, Robertson JR, Brettle RP, et al. Do gender differences in CD4 cell counts matter? AIDS 1999; 13:2361-4.
23. Jarrin I, Geskus R, Bhaskaran K, et al. Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women. Am J Epidemiol 2008; 168:532-40.
24. Anglaret X, Diabouga S, Mortier E, et al. CD41 T-lymphocyte counts in HIV infection: are European standards applicable to African patients. J Aquir Immune Defic Syndr Hum Retrovirol 1997; 14:361-7.
25. Howard RR, Fasano CS, Frey L, Miller CH. Reference intervals of CD3, CD4, CD8, CD4/CD8 and absolute CD4 values in Asian and non-Asian populations. Cytometry 1996; 26:231-2. (Pubitemid 26341319)
26. Webster HK, Pattanapanyasat K, Phanupak P, et al. Lymphocyte immunophenotype reference ranges in healthy Thai adults: implications of management of HIV/AIDS in Thailand. Southeast Asian J Trop Med Pub Health 1996; 27:418-29. (Pubitemid 126471608)
27. Silverberg MJ, Leyden W, Quesenberry CP, Horberg MA. Race/ethnicity and risk of AIDS and death among HIV-infected patients with access to care. J Gen Int Med 2009; 24(9):1065-72.